A biological avenue, not an established test
Metallothioneins are cysteine-rich proteins. They contribute to zinc and copper balance, bind certain toxic metals and help control oxidation-reduction reactions. Trace element imbalances, oxidative stress and immune alterations have been reported in autism, prompting research into these proteins.
This role provides a biological hypothesis, not proof that measuring metallothioneins could identify autism. The review specifically sought to determine whether human studies found a consistent change in this system.
Nine publications, no overall meta-analysis
The authors included nine publications: eight primary research reports and one secondary analysis. Eligible studies directly measured circulating proteins, metallothionein gene expression or antibodies against them in autistic people, their first-degree relatives, or both.
The literature searches were updated on September 5, 2026. Although targeted quantitative synthesis was performed where the data allowed, no meta-analysis pooling the results was conducted: the datasets were not sufficiently comparable. The abstract does not provide the total number of participants.
Results that do not converge
One study found no statistically significant difference in serum metallothioneins between autistic people and controls. A small cohort selected for its gastrointestinal context had more participants exceeding a high threshold defined by the study. This specific finding is not enough to establish a general characteristic of autism.
Five primary reports examined metallothionein gene expression. Depending on the forms studied and the blood-derived samples, results showed increases, decreases, no difference or inconsistencies within the same study. Findings on anti-metallothionein antibodies were also conflicting.
The zinc finding does not demonstrate a benefit
In a zinc supplementation study without a concurrent control group, serum metallothionein MT-1A increased, alongside a rise in serum zinc and a fall in copper. Without a comparator, the authors could not causally attribute these changes to supplementation.
These biological changes do not demonstrate clinical improvement in autism. The review therefore provides no basis for turning this observation into supplementation advice.
Limitations to keep in mind
Results vary across cohorts, biological samples and clinical contexts. The data cannot establish what explains these differences. Only the PubMed abstract was consulted, and funding and conflicts of interest were not checked.
What we can take away
This review validates neither a consistent alteration in metallothioneins in autism nor a usable biomarker. Above all, it highlights the need for independent studies, standardized measurements and better-characterized populations.
Sources and provenance
- Metallothionein-Related Findings in Autism Spectrum Disorder: A Systematic Review and Targeted Quantitative Synthesis of Human Studies.
Source date: 2026-10-13.
Journal Article, Systematic Review, Review · Résumé PubMed uniquement, texte intégral non consulté